A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults von Luskin, Marlise R., Murakami, Mark Alan, Keating, Julia, Winer, Eric S., Garcia, Jacqueline S., Stahl, Maximilian, Wadleigh, Martha, Flamand, Yael, Neuberg, Donna S., Galinsky, Ilene, Leonard, Rebecca, Hagopian, Ella, Weizer, Chase M, McLanahan, Carlin, Stone, Richard M, Wang, Eunice S., Stock, Wendy, DeAngelo, Daniel J.

Volltext